[Latest] Global White Hydrogen Market Size/Share Worth USD 15.11 Billion by 2034 at a 11.24% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

[Latest] Global White Hydrogen Market Size/Share Worth USD 15.11 Billion by 2034 at a 11.24% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis) [220+ Pages Latest Report] According to a market research study published by Custom Market Insights, the demand analysis of Global White Hydrogen Market size […]

MoonLake Immunotherapeutics’ (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit — Hagens Berman

MoonLake Immunotherapeutics' (MLTX) Reported Phase 3 Trial Data for Sole Drug Candidate, 90% Stock Crash Triggers Investor Suit — Hagens Berman GlobeNewswire November 24, 2025 SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) — MoonLake Immunotherapeutics (NASDAQ: MLTX), a clinical-stage biotechnology company, has been hit with a securities fraud class action lawsuit after its share price

James Hardie Industries (JHX) CFO Replaced, Lawsuit Alleging Securities Fraud Over Inventory Misstatements Pending — Hagens Berman

(NYSE:JHX), SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) — On November 17, 2025, James Hardie Industries plc (NYSE: JHX) announced the departure of its CFO (Rachel Wilson) who was immediately replaced by outsider Ryan Lada. This development follows the 34% August 20, 2025 collapse in James Hardie's share price and the class-action lawsuit filed against

James Hardie Industries (JHX) CFO Replaced, Lawsuit Alleging Securities Fraud Over Inventory Misstatements Pending — Hagens Berman

James Hardie Industries (JHX) CFO Replaced, Lawsuit Alleging Securities Fraud Over Inventory Misstatements Pending — Hagens Berman JHX Investors with Losses Encouraged to Contact Hagens Berman GlobeNewswire November 24, 2025 SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) — On November 17, 2025, James Hardie Industries plc (NYSE: JHX) announced the departure of its CFO (Rachel

Anchin Maintains Effective Security Controls According to Recent SOC 2 Report

Anchin, a leading accounting and advisory firm based in New York, announced that the company has undergone a System and Organization Controls (SOC) 2 examination resulting in an independent CPA's report stating that management of Anchin's system maintained effective controls over the security of clients', vendors', stakeholders', and referral sources' data. https://mma.prnewswire.com/media/2831313/Soc_2_Certification_from_BARR_Advisory.jpg The engagement was

Plume, Hyperliquid, & Aptos Lead the Inaugural Launch Cohort of Paxos’ USDG0 Omnichain Stablecoin

USDG0 brings fully backed, regulated stablecoin liquidity to high-growth DeFi environments, strengthening the next wave of onchain finance. Plume, the leading RWA blockchain powering real-world yield, today announced that it has joined Hyperliquid and Aptos as part of the inaugural launch cohort for USDG0 – a new omnichain version of the USDG stablecoin issued by

Freddie Mac Multifamily Loan Purchase Cap for 2026 is $88 Billion

(Other OTC:FMCC),(OTC US:FMCC), MCLEAN, Va., Nov. 24, 2025 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) Multifamily's loan purchase cap for 2026 will be $88 billion. The cap is set by U.S. Federal Housing largely based on projections for the size of the multifamily debt origination market. “Freddie Mac Multifamily delivers essential liquidity to create affordable

Freddie Mac Multifamily Loan Purchase Cap for 2026 is $88 Billion

Freddie Mac Multifamily Loan Purchase Cap for 2026 is $88 Billion GlobeNewswire November 24, 2025 MCLEAN, Va., Nov. 24, 2025 (GLOBE NEWSWIRE) — Freddie Mac (OTCQB: FMCC) Multifamily's loan purchase cap for 2026 will be $88 billion. The cap is set by U.S. Federal Housing largely based on projections for the size of the multifamily

Synopsys (SNPS) Exists Amidst Securities Class Action, IP Unit Scrutiny– Hagens Berman

(NASDAQ:SNPS), SAN FRANCISCO, Nov. 24, 2025 (GLOBE NEWSWIRE) — Synopsys, Inc. (NASDAQ: SNPS), a leading electronic design automation (EDA) company, is facing a significant leadership shakeup and escalating legal pressure, highlighted by the recent departure of its Chief Revenue Officer (CRO). The company announced in a Form 8-K filing on November 4, 2025, that Rick

CSE Bulletin: Notice of Distribution and Reclassification – PreveCeutical Medical Inc. (PREV)

Toronto, Ontario–(Newsfile Corp. – Le 24 novembre/November 2025) - PreveCeutical Medical Inc. (“PreveCeutical”) has announced the effective date of the reclassification as well as the previously announced plan of arrangement with BioGene Therapeutics Inc. (“BioGene”) to occur on November 25, 2025. Pursuant to the Arrangement Agreement (the “Arrangement Agreement”) 12,000,000 common shares of BioGene Therapeutics Inc.

Scroll to Top